8/9/2012 9:36:18 AM
SCHAUMBURG, Ill., Aug. 9, 2012 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Oxaliplatin for Injection, USP, the generic form of the chemotherapy drug, Eloxatin®, in two latex-free vial presentations. According to IMS data for the twelve-months ended June 2012, the U.S. market for Oxaliplatin for Injection, USP approximated $1.7 billion. As with all products in Sagent's portfolio, Oxaliplatin features the company's PreventIV MeasuresSM packaging and labeling designed to aid in the reduction of medication errors.
comments powered by